Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar;22(2):109-14.
doi: 10.1177/1076029615601494. Epub 2015 Aug 19.

Over 50 Years of Fibrinogen Concentrate

Rubens Costa-Filho  1 , Gerald Hochleitner  2 , Michael Wendt  3 , Alexandre Teruya  4 , Donat R Spahn  5
Affiliations
Review

Over 50 Years of Fibrinogen Concentrate

Rubens Costa-Filho et al. Clin Appl Thromb Hemost. 2016 Mar.

Abstract

March 2013 represented the 50th anniversary of the first license granted for a fibrinogen concentrate. In this review, we look at the history of bleeding management that led to the development of fibrinogen concentrate, discuss its current use, and consider future developments for this product.

Keywords: bleeding; blood coagulation factors; hemostasis.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: R.C-F. has no conflict of interest to declare. G.H. and M.W. are employees of CSL Behring. A.T. received lecture fees and travel support from CSL Behring. D.R.S. was the chairman of the ABC Faculty and is the co-chairman of the ABC-Trauma Faculty, which both are managed by Physicians World Europe GmbH, Mannheim, Germany and sponsored by unrestricted educational grants from Novo Nordisk Health Care AG, Zurich, Switzerland, CSL Behring GmbH, Marburg, Germany and LFB Biomédicaments, Courtaboeuf Cedex, France. In the past 5 years, D.R.S. has received honoraria or travel support for consulting or lecturing from the following companies: Abbott AG, Baar, Switzerland; AMGEN GmbH, Munich, Germany; AstraZeneca AG, Zug, Switzerland; Bayer (Schweiz) AG, Zürich, Switzerland; Baxter AG, Volketswil, Switzerland; Baxter S.p.A., Roma, Italy; B. Braun Melsungen AG, Melsungen, Germany; Boehringer Ingelheim (Schweiz) GmbH, Basel, Switzerland; Bristol-Myers-Squibb, Rueil-Malmaison Cedex, France and Baar, Switzerland; CSL Behring GmbH, Hattersheim am Main, Germany and Berne, Switzerland; Curacyte AG, Munich, Germany; Daiichi Sankyo (Schweiz) AG, Thalwil, Switzerland; Ethicon Biosurgery, Sommerville, New Jersey, USA; Fresenius SE, Bad Homburg v.d.H., Germany; Galenica AG, Bern, Switzerland (including Vifor SA, Villars-sur-Glâne, Switzerland); GlaxoSmithKline GmbH & Co. KG, Hamburg, Germany; Janssen-Cilag AG, Baar, Switzerland; Janssen-Cilag EMEA, Beerse, Belgium; Merck Sharp & Dohme AG, Luzern, Switzerland; Novo Nordisk A/S, Bagsvärd, Denmark; Octapharma AG, Lachen, Switzerland; Organon AG, Pfäffikon/SZ, Switzerland; Oxygen Biotherapeutics, Costa Mesa, CA, USA; PAION Deutschland GmbH, Aachen, Germany; Photonics Healthcare B.V., Utrecht, Netherlands; ratiopharm Arzneimittel Vertriebs-GmbH, Vienna, Austria; Roche Diagnostics International Ltd, Reinach, Switzerland; Roche Pharma (Schweiz) AG, Reinach, Switzerland; Schering-Plough International, Inc., Kenilworth, New Jersey, USA; Tem International GmbH, Munich, Germany; Verum Diagnostica GmbH, Munich, Germany; Vifor Pharma Deutschland GmbH, Munich, Germany; Vifor Pharma Österreich GmbH, Vienna, Austria; Vifor (International) AG, St. Gallen, Switzerland.

References

    1. Grebe MT, Luu B, Sedding D, et al. Fibrinogen promotes early atherosclerotic changes of the carotid artery in young, healthy adults. J Atheroscler Thromb. 2010;17(10):1003–1008. - PubMed
    1. Reinhart WH. Fibrinogen—marker or mediator of vascular disease? Vasc Med. 2003;8(3):211–216. - PubMed
    1. Stone MC, Thorp JM. Plasma fibrinogen—a major coronary risk factor. J R Coll Gen Pract. 1985;35(281):565–569. - PMC - PubMed
    1. Douglas S. Coagulation history, Oxford 1951-53. Br J Haematol. 1999;107(1):22–32. - PubMed
    1. Virchow R. Faserstoffarten und fibrinogene Substanz. Virchows Archiv. 1847;1(3):572–583.